• Privacy policy
  • T&C’s
  • About Us
    • FAQ
  • Contact us
  • Guest Content
  • TLE
  • News
  • Politics
  • Opinion
    • Elevenses
  • Business
  • Food
  • Travel
  • Property
  • JOBS
  • All
    • All Entertainment
    • Film
    • Sport
    • Tech/Auto
    • Lifestyle
    • Lottery Results
      • Lotto
      • Set For Life
      • Thunderball
      • EuroMillions
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
The London Economic
No Result
View All Result
Home Lifestyle Health

Warnings over using Ketamine as antidepressant

Previous studies have shown that the powerful horse tranquiliser used as an illegal dance drug has a rapid, calming and antidepressant effect

Ben Gelblum by Ben Gelblum
2018-08-29 12:05
in Health, Lifestyle, News, Science
(c) Psychonaut

(c) Psychonaut

FacebookTwitterLinkedinEmailWhatsapp

Rave drug ketamine cannot be used effectively as an antidepressant without risking addiction, warns new research.

Previous studies have shown that the powerful horse tranquiliser used as an illegal dance drug has a rapid, calming and antidepressant effect.

But researchers have now found that the effect only occurs when the opioid system – which controls pain, reward and addictive behaviour in the brain – is activated.

It is the first time that a receptor site has been shown in humans to be necessary for any antidepressant’s ability to work.

While opioids have been used historically to treat depression, they carry a high risk of dependence.

Researchers found that when the opioid receptors were blocked, the antidepressant effect was “dramatically reduced”.

Dr Alan Schatzberg, who led the research at Stanford University in the US, warned against widespread and repeated use of ketamine for depression treatment until more research can be done on both how the antidepressant effects are produced and the risk of tolerance, abuse and dependence.

Previously, the antidepressant effect of Ketamine had been generally thought to be due to it being a NMDA receptor antagonist – part of a class of anesthetics which produce a dissociative effect for the user.

Since many efforts to develop NMDA antagonists as antidepressants have been unsuccessful, the new study aimed at determining the role of the opioid system in ketamine’s antidepressant and dissociative effects in adults with treatment-resistant depression.

RelatedPosts

Gary Lineker says BBC should ‘hold its head in shame’ for not airing Gaza documentary

Donald Trump announces he plans to host UFC fight at the White House

Furniture as Art: Interview with Production and Design Expert Viktor Sobolevskyi

BBC to stop showing ‘high risk’ performances after Bob Vylan Glastonbury controversy

The authors of the study hypothesised that ketamine’s antidepressant effects may be intrinsically linked to setting off the opioid receptors in the brain.

The study, published in the American Journal of Psychiatry, looked at whether use of naltrexone, an opioid blocker, prior to ketamine treatment would reduce the acute antidepressant effects of the ketamine or its dissociative effects.

Participants received the opioid blocker or a placebo prior to ketamine infusion treatment.

Those who received the opioid blocker experienced a significant reduction in ketamine’s antidepressant effect, but not in the dissociative effects.

However, participants receiving the ketamine plus the opioid blocker experienced much less reduction in depression symptoms than participants receiving ketamine plus placebo.

Dr Mark George, of the Medical University of South Carolina, said of the findings: “We would hate to treat the depression and suicide epidemics by overusing ketamine, which might perhaps unintentionally grow the third head of opioid dependence.”

Dr George added: “With these new findings, we should be cautious about widespread and repeated use of ketamine before further mechanistic testing has been performed to determine whether ketamine is merely another opioid in a novel form.”

He also suggested more attention should be given to other underused treatments for depression and suicidality, including electroconvulsive therapy, transcranial magnetic stimulation and cervical vagus nerve stimulation.

By Ben Gelblum and  Grainne Cuffe

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

Contact

Editorial enquiries, please contact: [email protected]

Commercial enquiries, please contact: [email protected]

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

© The London Economic Newspaper Limited t/a TLE thelondoneconomic.com - All Rights Reserved. Privacy

No Result
View All Result
  • Home
  • News
  • Politics
  • Lottery Results
    • Lotto
    • Set For Life
    • Thunderball
    • EuroMillions
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Privacy policy
  • Contact us

© The London Economic Newspaper Limited t/a TLE thelondoneconomic.com - All Rights Reserved. Privacy

← First look behind scenes of multi-million pound Bear Grylls Adventure Park ← Hoppers Soho to host fundraising lunch in aid of Keralan Flood Relief
No Result
View All Result
  • Home
  • News
  • Politics
  • Lottery Results
    • Lotto
    • Set For Life
    • Thunderball
    • EuroMillions
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Privacy policy
  • Contact us

© The London Economic Newspaper Limited t/a TLE thelondoneconomic.com - All Rights Reserved. Privacy

-->